Cadila Healthcare Limited Announces Settlement with Depomed on Gralise

Cadila Healthcare Limited Announces Settlement with Depomed on Gralise® Ahmedabad, April 15, 2014 Cadila Healthcare Limited, a global pharmaceuticals company, and Zydus Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in the United States, today announced that they have entered into a settlement agreement with Depomed, Inc. to settle their ongoing patent infringement litigation related to Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling generic versions of Gralise® on January 1, 2024, or earlier under certain circumstances. Other terms of the settlement were not disclosed. The agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs 16,000 people worldwide and is dedicated to creating healthier communities globally. Zydus Cadila is the only Indian pharma company to launch its own patented NCE – Lipaglyn™, the world’s first drug to be approved for the treatment of diabetic dyslipidemia. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗